Natera, Inc. (NTRA), a molecular diagnostics company best known for its Signatera liquid-biopsy and non-invasive prenatal testing franchise, is widely covered by Wall Street, and the range of views is unusually wide. The overall average of all current analyst price targets sits near or slightly below the latest market price, which means the headline "average" target is not meaningfully above today's price. Because the minimum-distance rule requires a target at least 10% above the current price, the $470 figure used here is the mean of only the verified targets that are above the current price.
Eight current, attributable targets above the price were reviewed: Canaccord Genuity at $500, UBS at $490, TD Cowen at $480, Barclays at $475, Roth MKM at $475, JPMorgan at $460, Morgan Stanley at $435, and BTIG at $430. Their average is about $468, rounded to a central target of $470. For context, the overall mean of all valid targets is roughly $415, and the full Street range spans approximately $245 to $500. Bullish firms emphasize Signatera's dominance in molecular residual disease (MRD) testing and a long runway of reimbursement and guideline catalysts, while more cautious names such as Goldman Sachs and Wells Fargo point to valuation and profitability concerns.
The stock traded near $414 in late October 2026, after a powerful run that has seen it roughly double over the past year. Reaching $470 would require an advance of about 13% from that level—a substantial move that is plausible for a high-momentum growth stock but far from assured. The path toward the target would likely depend on continued execution: Q3 results due in early November, sustained Signatera volume growth, and progress toward positive cash flow. With the company still posting net losses even as revenue scales rapidly, the market is effectively paying for future profitability, which makes the shares sensitive to any stumble in growth or pricing.
Natera shares consolidated after a sharp rally, and market commentary has highlighted a breakout zone near $437 that traders have watched for confirmation of the uptrend's next leg. On the downside, the round-number $400 level represents a psychologically important support zone following a late-October pullback. A sustained close below $400 would suggest the consolidation is resolving lower, while a decisive push through the $437–$440 area would place the stock within reach of the $470 objective discussed here.
Analyst price targets generally reflect a roughly 12-month research horizon, though individual firms vary. The most important near-term catalyst is the Q3 2026 earnings report and conference call scheduled for November 5, when investors will scrutinize revenue against consensus of roughly $707 million, Signatera volume and ASP trends, and any update to full-year guidance. Beyond earnings, monitor NCCN and reimbursement decisions, MolDX coverage updates, competitive data readouts, and the company's progress toward positive free cash flow.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual screening alone. For those tracking names like NTRA, automated signal tools can help put daily price action into a broader, data-driven context.
Whether Natera can reach $470 depends on its ability to sustain exceptional growth while beginning to convert that growth into cash flow. The $470 target—the average of analyst targets above the current price—requires a move of about 13%, and it is supported by real momentum in Signatera adoption, regulatory tailwinds, and raised guidance. At the same time, the wide $245-to-$500 analyst range shows that the stock's premium valuation leaves meaningful downside risk if growth or pricing disappoints. The Q3 report and management's commentary on volumes, ASPs, and cash flow are the most important near-term signposts.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, NTRA has been loosely correlated with ADPT. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if NTRA jumps, then ADPT could also see price increases.
| Ticker / NAME | Correlation To NTRA | 1D Price Change % | ||
|---|---|---|---|---|
| NTRA | 100% | -8.54% | ||
| ADPT - NTRA | 55% Loosely correlated | -5.93% | ||
| NEO - NTRA | 55% Loosely correlated | -5.12% | ||
| GH - NTRA | 54% Loosely correlated | -4.51% | ||
| ISRG - NTRA | 53% Loosely correlated | +1.12% | ||
| TMO - NTRA | 48% Loosely correlated | -2.06% | ||
More | ||||